# Phase Summaries

## Phase Summary: Structure Build Validation

BioFuzz is implemented in the repository structure described by `BIOFUZZ_STRUCTURE.md`, including the core fuzzer loop, corpus/coverage subsystems, molecule preparation and mutation modules, docking interfaces, oracle logic, persistence helpers, scripts, target fixtures, and test suite.

This validation pass focused on confirming that the documented phases are represented coherently in code and that the repo remains runnable at the entrypoint level. The main challenges were distinguishing between real implementation gaps and environment-specific limitations: the codebase already covered the requested phases, but the current workspace lacks `rdkit`, `meeko`, and a docking binary, which prevents live execution of the chemistry-heavy completion criteria. To close the most visible spec gap that still existed inside the repository itself, I added regression coverage for `filters.py`, because the testing strategy explicitly includes that module.

Validation performed:

- `pytest -q` -> `27 passed, 8 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_buildpass_fresh` -> successful CLI smoke run

## Phase Summary: Spec Runtime Alignment

This follow-up phase tightened the runtime semantics so the implementation matches the design document more closely in the places that matter during an actual fuzzing run. The key changes were applying `config.yaml` oracle defaults to targets, computing coverage from heavy-atom contacts only, requiring a confirmation docking pass before findings are saved, and treating unavailable selectivity re-docks as skipped evidence instead of automatic failure.

The main challenge was that the remaining gaps were subtle: the repository already had the right module layout and passing tests, but some documented defaults and oracle behaviors were not truly wired through end-to-end. The target config model is also fully materialized, so global-target precedence had to be implemented using a default-value heuristic rather than a true partial-override schema.

Validation performed:

- `pytest -q` -> `32 passed, 8 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_spec_alignment_final` -> successful CLI smoke run

## Phase Summary: Develop Branch Build Verification

This request-level validation pass focused on confirming that the already-implemented BioFuzz repository still satisfies the structure document after reviewing the local agent instructions. The main code outcome was that no new implementation gaps were found: the package layout, target fixtures, scripts, tests, and phase-oriented modules described by `BIOFUZZ_STRUCTURE.md` are present in the current tree.

The meaningful work in this phase was operational. `.agent/AGENTS.md` requires active development on `develop`, but the workspace was still on `main`, so I moved the work onto a new `develop` branch before re-running verification. I also added a minimal `.gitignore` because generated Python caches and run artifacts were cluttering the working tree and obscuring source-level changes.

Validation performed:

- `pytest -q` -> `32 passed, 8 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_request_build` -> successful CLI smoke run

## Phase Summary: Request Refresh Validation

This request asked for another review of `.agent/AGENTS.md` and a current confirmation that BioFuzz is built according to `BIOFUZZ_STRUCTURE.md`. The implementation itself did not require new source edits during this pass: the repository still contains the documented package structure, target assets, scripts, config files, and tests covering the defined build phases.

The useful work here was fresh verification and status capture. I reran the available validation steps in the current environment, confirmed that the CLI entrypoint still initializes correctly, and recorded the remaining environment limitation explicitly: chemistry dependencies and docking engines are still not installed locally, so only the test suite and zero-iteration smoke run are executable in this workspace.

Validation performed:

- `pytest tests -q` -> `32 passed, 8 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_request_refresh` -> successful completion

## Phase Summary: Current Build Confirmation

This request asked for another review of `.agent/AGENTS.md` and a current confirmation that BioFuzz is built according to `BIOFUZZ_STRUCTURE.md`. The implementation itself still did not require source changes during this pass: the repository continues to match the documented package structure, target assets, scripts, configuration files, and phase-oriented test coverage.

The useful work here was a fresh end-to-end validation sweep and an updated record of what can be exercised in the present environment. The local workspace can still run the automated tests and the CLI initialization path, but it does not currently have the chemistry stack (`rdkit`, `meeko`) or a supported docking binary installed, so the full molecule-preparation and docking completion criteria remain environment-blocked rather than code-blocked.

Validation performed:

- `pytest tests -q` -> `32 passed, 8 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_request_current` -> successful completion

## Phase Summary: Build Reconfirmation

This request again asked for a review of `.agent/AGENTS.md` and a build confirmation against `BIOFUZZ_STRUCTURE.md`. The implementation still did not need source changes: the repository continues to provide the documented package structure, phase modules, scripts, targets, configuration, and tests described by the BioFuzz spec.

The useful work in this phase was a fresh verification pass plus an explicit dependency audit. The repository-level checks remain green, and the CLI entrypoint still initializes successfully. The only blockers to exercising the chemistry-heavy milestones locally are the absent third-party tools in this workspace: `rdkit`, `meeko`, and all supported docking binaries are unavailable, so the remaining limitation is environmental rather than structural.

Validation performed:

- `pytest tests -q` -> `32 passed, 8 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_request_new` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`

## Phase Summary: Spec Guardrails And Runtime Preflight

This phase moved beyond simple confirmation and tightened a set of subtle behaviors that could diverge from `BIOFUZZ_STRUCTURE.md` under real use. The main code changes made oracle/global-config precedence explicit per field, made Meeko-backed ligand preparation strict by default with an opt-in fallback path, prevented stale coverage checkpoints from redefining the live target pocket, reapplied the active corpus size cap after resume, required findings to copy a real pose file, and added CLI preflight checks so a live fuzzing run fails immediately when `rdkit`, `meeko`, or a docking binary are unavailable.

The main challenge was that the repo already looked complete and passed its visible tests, so the remaining work was mostly hidden-edge hardening rather than feature building. That made it important to add targeted regression coverage for the exact failure modes being fixed: cwd-vs-target receptor resolution, explicit default oracle overrides, stricter preparation semantics, checkpoint mismatch handling, resumed corpus trimming, findings-store pose validation, and zero-iteration CLI smoke behavior.

Validation performed:

- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_build_request_hardening_v2` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- `python3 main.py --target hiv_protease --max-iterations 1 --workers 1 --output runs/smoke_cli_2026_03_29_preflight_check` -> expected preflight failure reporting missing `RDKit`, `Meeko`, and `gnina`

## Phase Summary: User Build Validation

This request asked for another review of `.agent/AGENTS.md` and for BioFuzz to be built as defined by `BIOFUZZ_STRUCTURE.md`. The implementation itself did not require further code changes during this pass because the repository already contains the documented package layout, target fixtures, scripts, configuration, and tests for phases 1-10, and the current test suite remains green.

The useful work in this phase was a fresh request-scoped verification sweep and an updated dependency audit. I reran the full test suite and the zero-iteration CLI smoke path, then confirmed that the remaining inability to execute chemistry-heavy milestones locally is still caused by absent runtime dependencies rather than missing repository functionality.

Validation performed:

- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_request_user_build` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Current Request Build Refresh

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. The repository still did not require source-code changes during this pass because the documented package layout, phase modules, target fixtures, scripts, configuration, and tests remain present and coherent in the workspace.

The useful work here was a fresh verification sweep against the current tree rather than relying on earlier confirmations. I reran the full test suite, reran the zero-iteration CLI smoke path, confirmed that development is still happening on `develop`, and repeated the dependency audit so the remaining runtime limits are clearly recorded as environment issues rather than implementation gaps.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_current_request` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Request Build Reaudit

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh source audit found that the current repository still already satisfies the documented package structure, module split, target assets, scripts, configuration, and phase-oriented tests, so no BioFuzz source-code changes were necessary.

The useful work in this phase was validating the live tree directly instead of depending on prior request logs. I rechecked the required branch, reran the full test suite, reran the zero-iteration CLI smoke path, and recorded the result as a completed execution plan so this request has its own traceable audit record.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_current_request_2` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: AGENTS Review And Structure Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the live repository found that the implementation already satisfies the documented package structure, module split, target assets, scripts, configuration, and phase-oriented test coverage, so no new BioFuzz source-code changes were required.

The useful work in this phase was current-state verification rather than rebuilding existing code. I rechecked the required `develop` branch, reran the full test suite, reran the zero-iteration CLI smoke path, and repeated the dependency audit so the remaining execution limits are explicitly recorded as environment constraints instead of implementation gaps.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_latest_request` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Current Build Confirmation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the live repository again found that the implementation already satisfies the documented package structure, module split, target assets, scripts, configuration, and phase-oriented test coverage, so no new BioFuzz source-code changes were required.

The useful work in this phase was a clean verification pass against the current workspace rather than prior request history. I rechecked the required `develop` branch, reran the full test suite, reran the zero-iteration CLI smoke path, and repeated the dependency audit so the remaining runtime limits are clearly recorded as environment constraints instead of implementation gaps.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_request_agents_review_build` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Live Build Verification

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the live repository and key runtime entrypoints again found that the implementation already satisfies the documented package structure, module split, target assets, scripts, configuration, and phase-oriented test coverage, so no BioFuzz source-code changes were required.

The useful work in this phase was validating the current workspace directly instead of trusting prior summaries. I rechecked the required `develop` branch, reread the key fuzzer, preparation, runner, and CLI entrypoint modules, reran the full test suite, reran the zero-iteration CLI smoke path, and repeated the dependency audit so the current state is documented precisely. The remaining limitation is still environmental: the chemistry stack and supported docking binaries are absent from this workspace, so the full preparation and docking milestones cannot be exercised end-to-end here.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_current_request_3` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Current Build Reverification

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the current live repository again found that the implementation already satisfies the documented package structure, phase module split, targets, scripts, configuration, and test coverage, so no BioFuzz source-code changes were required.

The useful work in this phase was current-state reverification rather than new implementation. I reread the governing AGENTS instructions, rechecked the required `develop` branch, confirmed the key runtime modules still line up with the documented build phases, reran the full test suite, reran the zero-iteration CLI smoke path into a fresh output directory, and repeated the dependency audit. The remaining limitation is still environmental: the chemistry stack and supported docking binaries are absent from this workspace, so the full preparation and docking milestones cannot be exercised end-to-end here.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_29_user_request_fresh` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Request Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the live repository found that the implementation still already satisfies the documented package layout, phase module split, target assets, scripts, configuration, and tests, so no new BioFuzz source-code changes were required.

The useful work in this phase was validating the current workspace directly and recording that result in the required project-tracking artifacts. I rechecked the required `develop` branch, reread the key runtime modules that define the main loop and docking/preparation path, reran the full test suite, reran the zero-iteration CLI smoke path into a fresh output directory, and repeated the dependency audit. The remaining limitation is still environmental: the chemistry stack and supported docking binaries are absent from this workspace, so the full preparation and docking milestones cannot be exercised end-to-end here.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_current_request` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Live Build Audit

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the current live repository found that the implementation still already satisfies the documented package layout, main loop structure, preparation and docking interfaces, target assets, configuration, scripts, and test coverage, so no new BioFuzz source-code changes were required.

The useful work in this phase was a direct live-tree audit rather than relying on the existing request history under `.agent/`. I reread the governing instructions, re-audited the main runtime modules, rechecked the required `develop` branch, reran the full test suite, reran the zero-iteration CLI smoke path into a fresh output directory, and repeated the dependency audit. The remaining limitation is still environmental: the chemistry stack and supported docking binaries are absent from this workspace, so the full preparation and docking milestones cannot be exercised end-to-end here.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_current_2` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Request Review And Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh request-scoped audit of the live repository found that the implementation still already satisfies the documented package layout, target fixtures, scripts, configuration, entrypoint, and runtime modules for phases 1-10, so no new BioFuzz source-code changes were required.

The useful work in this phase was recording a current validation pass against the live tree rather than assuming previous confirmations still applied. I rechecked the required `develop` branch, confirmed the package structure and key runtime modules still line up with the design document, reran the full test suite, reran the zero-iteration CLI smoke path into a fresh output directory, and repeated the dependency audit. The remaining limitation is still environmental: the chemistry stack and supported docking binaries are absent from this workspace, so the preparation and docking milestones cannot be executed end-to-end here.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_biofuzz` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Request Live Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh live-tree audit found that the repository still already satisfies the documented package layout, targets, scripts, configuration, entrypoint, and runtime module split for phases 1-10, so no new BioFuzz source-code changes were required.

The useful work in this phase was a current validation sweep and an explicit check that the repository inventory still matches the structure document. I rechecked the required `develop` branch, reran the full test suite, reran the zero-iteration CLI smoke path into a fresh output directory, confirmed the expected target and script files are present, and repeated the dependency audit. The remaining limitation is still environmental: the chemistry stack and supported docking binaries are absent from this workspace, so the live molecule-preparation and docking milestones cannot be exercised end-to-end here.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `39 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_build_live` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Inventory audit -> confirmed `targets/hiv_protease/{config.py,protein.pdbqt,reference_ligands/indinavir.smi,reference_ligands/indinavir.pdbqt}` and `scripts/{download_zinc.py,prep_protein.sh,visualize_hit.py}` are present
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Preflight Binary Alignment

This follow-up phase fixed a real runtime mismatch discovered during the fresh audit. The repository already matched `BIOFUZZ_STRUCTURE.md` structurally, but `main.py` was stricter than the actual docking layer: the CLI preflight rejected a run unless the configured docking engine existed exactly, even though `biofuzz.docking.runner` already knows how to fall back to another supported binary when one is available. That meant the entrypoint could block a run that the docking subsystem itself would have executed successfully.

The fix was deliberately small. I changed runtime dependency detection to use the same docking-binary resolution logic as the runner and added regression coverage for the supported-fallback case. This keeps the CLI guardrail intact while making it faithful to the real runtime behavior.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `40 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_preflight_alignment` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Environment note -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace, so chemistry-heavy milestones remain environment-blocked rather than code-blocked

## Phase Summary: Current Live Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the current live repository found that the implementation still already satisfies the documented package layout, phase module split, targets, scripts, configuration, and test coverage, so no new BioFuzz source-code changes were required.

The useful work in this phase was a current verification sweep against the live tree rather than relying on previous request summaries. I re-read the governing instructions, confirmed the repository is still on `develop`, re-audited the key runtime modules and expected structure inventory, reran the full test suite, and reran the zero-iteration CLI smoke path. One small environment detail surfaced during verification: this workspace exposes `python3` but not a `python` alias, so the validated local entrypoint command here is `python3 main.py ...`. The remaining chemistry-heavy limitations are still environmental rather than structural because `rdkit`, `meeko`, and supported docking binaries are not installed in this workspace.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `40 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Environment note -> `python3` available, `python` alias absent; `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Current Tree Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the current live tree found that the repository still already satisfies the documented package layout, targets, scripts, configuration, entrypoint, and runtime module split for phases 1-10, so no new BioFuzz source-code changes were required.

The useful work in this phase was validating the live tree directly and updating the required project tracking with a current snapshot. I re-read the governing instructions, re-audited the key runtime modules, reconfirmed the expected target and script inventory, reran the full test suite, reran the zero-iteration CLI smoke path into a fresh output directory, and repeated the dependency audit. The remaining limitation is still environmental: `rdkit`, `meeko`, and all supported docking binaries are absent from this workspace, so the chemistry-heavy phases cannot be exercised end-to-end here.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `40 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_build_current` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- Inventory audit -> confirmed `targets/hiv_protease/{config.py,protein.pdbqt,reference_ligands/indinavir.smi,reference_ligands/indinavir.pdbqt}` and `scripts/{download_zinc.py,prep_protein.sh,visualize_hit.py}` are present
- Dependency audit -> `yaml` available; `rdkit`, `meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Persistent Scheduler, Power Schedule, TUI, And Expanded Targets

This phase turned BioFuzz from a bounded queue processor into a more AFL-like live fuzzer. The main loop now keeps running until interrupted, requeues previously seen corpus entries instead of draining them away, deduplicates corpus members by SMILES, and applies a simple power schedule so entries that found new coverage, better affinities, or hits receive larger future mutation budgets. A throttled TTY-only TUI now surfaces the same scheduler and docking telemetry during live runs without changing non-TTY behavior.

The biggest engineering challenge was making the new runtime semantics fit the existing architecture cleanly. The corpus had to remain checkpointable and resumable while changing from a one-shot priority queue into a persistent structure, the loop needed to count confirmation and selectivity docks accurately for the runtime UI, and the new progress plumbing could not make the test suite brittle. The target-expansion work had a different challenge: generating real receptor PDBQT/config/reference assets reproducibly instead of checking in hand-built examples. To solve that, I added `.agent/tools/prepare_target_fixture.py` and used it to derive receptor chains, ligand-centered docking boxes, pocket residue lists, and reference ligand assets from known co-crystal structures.

Validation performed:

- `.venv/bin/python -m pytest tests -q` -> `58 passed`
- `.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: True`
- Local Vina sanity docks for new bundled targets -> `egfr_kinase -7.161`, `parp1 -12.15`, `sars_cov2_mpro -8.344`, `braf_v600e -10.09` kcal/mol
- `.venv/bin/python main.py --target egfr_kinase --engine vina --seeds /tmp/biofuzz_smoke_seed.smi --mutations-per-entry 1 --max-iterations 1 --workers 1 --output runs/smoke_cli_2026_04_10_scheduler_tui_egfr` -> successful one-iteration live run

## Phase Summary: Live CLI Regression Coverage

This phase turned the previously manual live-run validation into a repeatable regression in the normal test suite. BioFuzz already had a working `.venv` runtime, a repo-local Vina binary, and checked-in HIV protease assets, but the real one-iteration CLI path was still protected only by ad hoc smoke commands and `.agent/` notes. I added a bounded subprocess regression in `tests/test_main.py` that launches `main.py` against the checked-in `hiv_protease` target with a single phenol seed, asserts the run completes one real docking iteration, and verifies the expected checkpoint files are written.

The main challenge was keeping the regression high-signal without making it brittle. The live docking path depends on RDKit, Meeko, and a resolved Vina binary, so the test had to skip cleanly when that runtime is unavailable while still exercising the actual CLI, preparation, docking, checkpointing, and output-reporting path when it is present. I kept the run bounded to one iteration and one mutation budget so it stays fast enough for routine `pytest` use, then updated `README.md` to make it clear that the normal verification path now covers a real end-to-end docking execution when the runtime toolchain is installed.

Validation performed:

- `.venv/bin/python -m pytest tests/test_main.py -q` -> `5 passed in 2.14s`
- `.venv/bin/python -m pytest tests -q` -> `60 passed in 2.44s`
- `.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: True`; repo-local `vina` resolved from `.agent/tools/bin/vina`

## Future Work

The next useful hardening step is to add a similarly bounded live regression for the multiprocessing path (`--workers 2`) once a low-runtime fixture strategy is pinned down. That would extend protection from the one-worker CLI loop to the parallel docking path as well; the main challenge is keeping process startup and docking variability low enough that the test remains fast and stable for everyday `pytest` runs.

## Phase Summary: Current Workspace Runtime Audit

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh workspace audit again found that the repository already satisfies the documented package layout, targets, scripts, configuration, entrypoint, and runtime module split, so the BioFuzz implementation itself did not need new functional source changes.

The useful work in this phase was making the repeated environment check reproducible instead of redoing it manually on each validation pass. I added `.agent/tools/runtime_audit.py` to report the availability of the Python chemistry stack and supported docking binaries, then reran the current verification flow against the live workspace. That keeps future build confirmations faster and makes the remaining blocker explicit: the codebase is built, but this machine still lacks the chemistry/runtime toolchain needed for non-zero docking runs.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `40 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_runtime_audit` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Current Workspace Revalidation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the current workspace found that the repository still already satisfies the documented package layout, runtime module split, targets, scripts, configuration, and tests for phases 1-10, so no new BioFuzz source-code changes were required.

The useful work in this phase was current-state verification instead of reimplementation. I re-read the governing instructions, re-audited the key runtime modules, reran the full test suite, reran the zero-iteration CLI smoke path into a fresh output directory, and reran the runtime dependency audit. The remaining limitation is still environmental: the machine does not have `RDKit`, `Meeko`, or any supported docking binary installed, so the chemistry-heavy phases cannot be exercised end-to-end here even though the repository structure and code paths are in place.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `40 passed, 10 skipped`
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Current Workspace Status Documentation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the current workspace found that the repository still already satisfies the documented package layout, entrypoint, runtime modules, targets, scripts, configuration, and tests for phases 1-10, so the implementation itself did not require new functional changes.

The useful work in this phase was to turn the live validation result into clearer repository guidance instead of leaving it buried only in `.agent/` tracking files. I re-read the governing instructions, revalidated the current workspace with the available checks, confirmed the project is still on `develop`, and updated `README.md` with the exact local verification path that succeeds in this environment. That makes the current state explicit: the codebase is built to spec, while non-zero docking runs remain blocked only by missing runtime dependencies.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest tests -v` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace

## Phase Summary: Latest Workspace Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live repository found that the implementation still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was current-state verification rather than rebuilding existing project code. I re-read the governing instructions, re-audited the key runtime modules, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path into a fresh output directory. The remaining limitation is still environmental: the workspace does not have `RDKit`, `Meeko`, or any supported docking binary installed, so the chemistry-heavy phases cannot be exercised end-to-end here even though the repository is built to the structure spec.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_latest` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`

## Phase Summary: Current Request Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh live audit of the repository found that the implementation still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was current-state verification rather than rebuilding existing project code. I re-read the governing instructions, re-audited the key runtime modules, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path into a fresh output directory for this request. The remaining limitation is still environmental: the workspace does not have `RDKit`, `Meeko`, or any supported docking binary installed, so the chemistry-heavy phases cannot be exercised end-to-end here even though the repository is built to the structure spec.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_request` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`

## Phase Summary: Current Session Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the current live workspace found that the repository still already satisfies the documented package layout, module split, targets, scripts, configuration, entrypoint, and test coverage, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was current-session verification against the live tree instead of relying on prior request tracking. I re-read the governing instructions, re-audited the key runtime modules including the config/oracle wiring, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path into a fresh output directory for this request. The remaining limitation is still environmental: the workspace does not have `RDKit`, `Meeko`, or any supported docking binary installed, so the chemistry-heavy phases cannot be exercised end-to-end here even though the repository is built to the structure spec.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest -q` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_session` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, `best_affinity=0.0`

## Phase Summary: Workspace Validation Refresh

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the current live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and supporting tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was a clean current-workspace validation sweep rather than additional implementation. I re-read the governing instructions, re-audited the key runtime modules across the fuzzer, preparation, mutation, docking, oracle, and config layers, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path. The result remains the same: the repository is built to the structure spec, while non-zero chemistry/docking execution is blocked only by missing local runtime dependencies.

Validation performed:

- `pytest tests -v` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, and `best_affinity=0.0`

## Phase Summary: Current BioFuzz Status Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the live repository found that the implementation still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, and test coverage, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was current-state verification against the live tree rather than rebuilding code that is already present. I re-read the governing instructions, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a fresh output directory, and rechecked the expected target/reference files. The outcome remains consistent: the repository is built to the structure spec, while non-zero chemistry and docking execution is blocked only by missing local runtime dependencies.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest tests -v` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_current_request_final` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, and `best_affinity=0.0`

## Phase Summary: Fresh Validation Pass

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the current repository found that the implementation still already satisfies the documented package layout, phase/module split, target assets, scripts, configuration, entrypoint, and test coverage, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was a clean, request-scoped validation sweep against the live workspace instead of relying on prior request history. I re-read the governing instructions, re-audited the key runtime and target-configuration modules, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a fresh output directory, and rechecked the required seed/target/script assets. The conclusion remains unchanged: the repository is built to the structure spec, while non-zero chemistry and docking execution is blocked only by missing local runtime dependencies.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_fresh_validation` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, and `best_affinity=0.0`

## Phase Summary: Live Workspace Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh live-workspace audit found that the implementation already satisfies the documented package layout, phase/module split, target fixtures, scripts, configuration, entrypoint, and test coverage, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was confirming the current repository state directly instead of assuming earlier audits still applied. I re-read the governing instructions, re-audited the key runtime modules that cover the fuzzer loop, preparation path, docking wrapper, affinity oracle, and pocket fingerprinting, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path into a fresh output directory. The conclusion remains unchanged: the repository is built to the structure spec, while live non-zero chemistry and docking execution is still blocked only by missing local runtime dependencies.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest -q` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_biofuzz_current` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, and `best_affinity=0.0`

## Phase Summary: Current Turn Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh live audit of the current repository found that the implementation still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was a direct code/spec audit across the current phase boundaries rather than relying on earlier request logs. I re-read the governing instructions, re-audited the main loop plus the parsing, coverage, residue-contact, oracle, and preparation layers, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path into a fresh output directory. The conclusion remains unchanged: the repository is built to the structure spec, while the chemistry-heavy phases are still blocked only by missing local runtime dependencies.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest tests -v` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_build_current_turn` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=6`, and `best_affinity=0.0`

## Phase Summary: Seed Corpus Refresh And Downloader Hardening

This pass went beyond another confirmation sweep and fixed a concrete repository mismatch against `BIOFUZZ_STRUCTURE.md`. The project structure document calls for `seeds/zinc_druglike_10k.smi` as the initial ZINC20-derived seed corpus, but the live workspace still held only a tiny development placeholder and the downloader script still targeted the obsolete `drug-like.smi` endpoint.

The useful work in this phase was replacing that placeholder with a real seed corpus and updating the supporting utility so the repository can refresh it repeatably. I changed `scripts/download_zinc.py` to use the current official ZINC20 subset export path, paginate requests in smaller batches, send explicit request headers, retry transient page failures, and stream results directly to disk. I then regenerated `seeds/zinc_druglike_10k.smi` to 10,000 entries and reran the full validation path. The repository now matches the documented seed-corpus expectation much more closely, while the remaining inability to run non-zero docking iterations is still caused only by missing local chemistry/runtime dependencies.

Validation performed:

- `python3 -m pytest tests -v` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_seed_refresh` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`

## Phase Summary: Current Task Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the current live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was verifying the current tree directly after the seed-corpus refresh instead of assuming prior validation still applied. I re-read the governing instructions, re-audited the key runtime modules for the main loop, preparation path, docking runner, and oracle flow, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a fresh output directory, and reconfirmed the repository is still on `develop`. The conclusion remains unchanged: the repository is built to the structure spec, while live non-zero chemistry and docking execution is still blocked only by missing local runtime dependencies.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -v` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_task` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`

## Phase Summary: Current Runtime Snapshot

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh live-tree audit found that the repository still already satisfies the documented package layout, phase/module split, target fixtures, scripts, configuration, entrypoint, and test coverage, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a clean current-state snapshot from the live workspace rather than depending on prior request history. I re-read the governing instructions, rechecked the package tree and the key runtime modules that wire the CLI, fuzzer loop, docking config, docking runner, and molecule-preparation path together, reconfirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path into a fresh output directory. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest -q` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_runtime_snapshot` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`

## Phase Summary: Final Request Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the current live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was validating the live repository directly instead of depending on the existing chain of `.agent/` confirmations. I re-read the governing instructions, re-audited the current CLI entrypoint plus the main loop, preparation, docking, parsing, coverage, and oracle layers, reconfirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path into a fresh output directory. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest tests -v` -> `40 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_final_validation` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`

## Phase Summary: Corpus Checkpoint Layout Alignment

This pass again started from a fresh review of `.agent/AGENTS.md` and a live audit against `BIOFUZZ_STRUCTURE.md`, but it found one remaining concrete repository-level mismatch instead of stopping at another confirmation sweep. The runtime output layout still checkpointed the evolving corpus only as `runs/.../corpus.json`, while the structure document explicitly defines `runs/.../corpus/` as the location for corpus state.

The fix was intentionally narrow. I updated the fuzzer to save corpus state primarily to `runs/<stamp>_<target>/corpus/state.json`, to resume from that path when present, and to fall back to legacy top-level `corpus.json` checkpoints so the many existing runs in this workspace remain usable. To avoid breaking older workflows outright, the fuzzer now also mirrors saves back to `corpus.json`. I added regression coverage for the new layout and precedence rules, updated the README status note, and re-ran the repository verification path. The repository now matches the documented run-output structure more closely, while the only remaining blocker for live non-zero chemistry and docking runs is still the missing local runtime toolchain.

Validation performed:

- `python3 -m pytest tests -q` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_corpus_layout_alignment` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_corpus_layout_alignment/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current Spec Validation Refresh

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was current-state verification against the live tree instead of relying on the earlier request log chain. I re-read the governing instructions, re-audited the main runtime modules, reconfirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path into a fresh output directory. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while live non-zero chemistry and docking execution is still blocked only by missing local runtime dependencies.

Validation performed:

- `git branch --show-current` -> `develop`
- `pytest tests -q` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_validation_2` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`

## Phase Summary: Current User-State Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was a clean current-state validation against the live tree rather than relying on the earlier chain of `.agent/` confirmations. I re-read the governing instructions, re-audited the current CLI entrypoint plus the core fuzzer, corpus, coverage, docking, preparation, mutation, oracle, and protein-contact modules, reconfirmed the repository remains on `develop`, verified that the seed corpus still contains the documented 10,000 entries, reran the full test suite, reran the runtime dependency audit, and reran the zero-iteration CLI smoke path into a fresh output directory. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -v` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Inventory audit -> confirmed `seeds/zinc_druglike_10k.smi` has 10,000 entries and `targets/hiv_protease/{config.py,protein.pdbqt,reference_ligands/indinavir.smi,reference_ligands/indinavir.pdbqt}` are present

## Phase Summary: Current User Prompt Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was validating the live repository directly for the current user prompt instead of relying on the long chain of earlier `.agent/` confirmations. I re-read the governing instructions, re-audited the current CLI entrypoint together with the core fuzzer, corpus, coverage, docking, preparation, mutation, oracle, and protein-contact modules, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a fresh output directory, and reconfirmed the documented inventory state for the seed corpus, HIV protease target assets, and standalone scripts. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `python3 -m pytest tests -v` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_prompt` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Inventory audit -> confirmed `seeds/zinc_druglike_10k.smi` has 10,000 entries, `targets/hiv_protease/{config.py,protein.pdbqt,reference_ligands/indinavir.smi,reference_ligands/indinavir.pdbqt}` are present, and `scripts/{download_zinc.py,prep_protein.sh,visualize_hit.py}` are present

## Phase Summary: Fresh Current-Request Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the current live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was making the validation record truly fresh for the current request instead of resuming a previously used smoke-run directory. I re-read the governing instructions, re-audited the current CLI entrypoint together with the core fuzzer, corpus, coverage, docking, preparation, mutation, oracle, and protein-contact modules, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a new output directory, and confirmed that the documented run layout was produced with `coverage.json` plus `corpus/state.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest -q` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_prompt_fresh` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_prompt_fresh/{coverage.json,corpus/state.json}`

## Phase Summary: Fresh Current-Turn Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was validating the live repository directly for the current turn instead of depending on the earlier request trail under `.agent/`. I re-read the governing instructions, re-audited the current CLI entrypoint together with the corpus, coverage, docking, preparation, mutation, oracle, and protein-contact modules, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json` plus `corpus/state.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest -q` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_turn_2_fresh` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_turn_2_fresh/{coverage.json,corpus/state.json}`

## Phase Summary: Fresh Current-Turn Validation 3

This turn again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was making the validation record fresh for this exact turn with a new smoke-run output directory rather than relying on earlier request-level confirmations. I re-read the governing instructions, reconfirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -v` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_turn_3` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_turn_3/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Fresh Current User-State Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was making the validation artifact fresh for this exact request instead of reusing a smoke-run directory that already contained resume checkpoints. I re-read the governing instructions, reconfirmed the repository remains on `develop`, re-audited the current CLI entrypoint together with the core fuzzer, corpus, coverage, docking, preparation, mutation, oracle, and protein-contact modules, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a new output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -v` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_fresh` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_fresh/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Fresh Current User-State Validation Refresh

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a request-specific verification record with a new smoke-run output directory instead of reusing an earlier current-user-state validation path. I re-read the governing instructions, reconfirmed the repository remains on `develop`, re-audited the current CLI entrypoint together with the core fuzzer, corpus, coverage, docking, preparation, mutation, oracle, and protein-contact modules, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a new output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -v` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_fresh_2` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_fresh_2/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current Request Build Confirmation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a request-specific verification record instead of relying on the earlier `.agent/` validation chain. I re-read the governing instructions, reconfirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a new output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -q` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_current_request_build` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_current_request_build/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Fresh Current Request Build Confirmation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace again found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was eliminating resume ambiguity from the verification record for this exact request. I re-read the governing instructions, rechecked the key entrypoint and runtime modules, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a new output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `python3 -m pytest -q` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_current_request_build_fresh_2` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_current_request_build_fresh_2/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current Prompt Runtime Validation

This prompt again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace again found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a prompt-specific validation record instead of relying on earlier request history. I re-read the governing instructions, reconfirmed the repository remains on `develop`, re-audited the current entrypoint and the main runtime modules for corpus management, coverage, docking, preparation, mutation, oracle evaluation, and protein-contact parsing, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -v` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_prompt` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_prompt/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current User-State Turn Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace again found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was creating a request-specific validation record for the current turn rather than relying on the earlier `.agent/` confirmation chain. I re-read the governing instructions, reconfirmed the repository remains on `develop`, re-audited the current entrypoint and the main runtime modules for docking, preparation, mutation, oracle evaluation, and protein-contact parsing, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -v` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_turn` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_turn/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Agent Guidance Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a fresh request-specific verification artifact instead of relying on prior `.agent/` request history or a reused smoke-run directory. I re-read the governing instructions, reconfirmed the repository remains on `develop`, rechecked the core runtime modules against the structure document, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a new output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest -q` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agent_guidance_and_build_workspace` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agent_guidance_and_build_workspace/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current User-State Latest Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace again found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was creating a new request-specific verification artifact instead of relying on the existing `.agent/` validation chain. I re-read the governing instructions, reconfirmed the repository remains on `develop`, rechecked the current entrypoint and runtime modules for corpus management, coverage, docking, preparation, mutation, oracle evaluation, and protein-contact parsing, reran the full test suite, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -q` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_latest` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_latest/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current User-State Latest Validation 2

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace again found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was generating a new request-specific verification artifact instead of reusing the previous current-user-state validation record. I re-read the governing instructions, reconfirmed the repository remains on `develop`, reran the full test suite in verbose mode, reran the runtime dependency audit, reran the zero-iteration CLI smoke path into a new output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is still the missing local runtime toolchain.

Validation performed:

- `git branch --show-current` -> `develop`
- `python3 -m pytest tests -v` -> `41 passed, 10 skipped`
- `python3 .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML` available; `RDKit`, `Meeko`, `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `python3 main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_latest_2` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_latest_2/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Python Dependency Build Alignment

This request started as another AGENTS/spec validation pass, but the live build work uncovered a real packaging problem inside the repository: `requirements.txt` still referenced `rdkit-pypi`, which does not resolve in the current Python 3.12 environment, and the Meeko path looked superficially installed while actually failing at import time because its undeclared runtime dependencies were missing. That meant the repository looked built on paper but did not provide a clean reproducible local Python environment for the documented molecule-preparation phase.

The successful approach was to make the smallest changes that turn the current repository into a working local build. I switched the RDKit requirement to the actively published `rdkit` package, explicitly added `scipy` and `gemmi` so Meeko imports cleanly, added `.venv/` to `.gitignore`, and hardened `.agent/tools/runtime_audit.py` to import modules instead of only checking whether they are discoverable on disk. I also updated the README's repository-status section so the validated local flow matches the current environment: create `.venv`, install the requirements, run the tests, run the runtime audit, and use `.venv/bin/python` for the smoke path.

This phase materially improved the live build state. After the dependency fixes, the full test suite passed without skips in the virtualenv, the Phase 1 completion criterion (`prepare_smiles()` on aspirin producing `TORSDOF`) passed, and the CLI zero-iteration run still completed successfully. The only remaining blocker to a real non-zero docking run is external to the repository: no supported docking binary is installed on this machine.

Validation performed:

- `.venv/bin/pip install -r requirements.txt` -> successful local virtualenv install of `PyYAML`, `rdkit`, `scipy`, `gemmi`, `meeko`, and `pytest`
- `.venv/bin/python -m pytest tests -v` -> `51 passed`
- `.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable
- `.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_user_state_latest_3_venv_final` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- `.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; ..."` -> `Phase 1 OK`

## Phase Summary: Current User-State Latest Validation 4

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository still already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was validating the repository through the repaired local `.venv` build path instead of relying on the older confirmation chain. I re-read the governing instructions, confirmed the repository remains on `develop`, reran the full test suite in `.venv`, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/pytest -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; pdbqt = prepare_smiles('CC(=O)Oc1ccccc1C(=O)O'); assert pdbqt is not None; assert 'TORSDOF' in pdbqt; print('Phase 1 OK')"` -> `Phase 1 OK`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_latest_4` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_latest_4/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current User-State Latest Validation 5

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace again found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing one more request-specific verification artifact against the current `.venv` environment instead of relying on the prior validation chain. I re-read the governing instructions, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; pdbqt = prepare_smiles('CC(=O)Oc1ccccc1C(=O)O'); assert pdbqt is not None; assert 'TORSDOF' in pdbqt; print('Phase 1 OK')"` -> `Phase 1 OK`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_latest_5` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_user_state_latest_5/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current Request Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a current-request verification artifact from the repaired `.venv` path instead of relying on the earlier `.agent/` confirmation chain. I re-read the governing instructions, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reran the zero-iteration CLI smoke path into a fresh output directory, and reconfirmed that the repository is built to the structure spec. The conclusion remains unchanged: the only remaining blocker for live non-zero docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; pdbqt = prepare_smiles('CC(=O)Oc1ccccc1C(=O)O'); assert pdbqt is not None; assert 'TORSDOF' in pdbqt; print('Phase 1 OK')"` -> `Phase 1 OK`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_current_request_build_fresh_3` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_current_request_build_fresh_3/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current Turn Build Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a fresh request-scoped verification result from the repaired `.venv` path instead of relying on the earlier `.agent/` confirmation chain. I re-read the governing instructions, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reran the zero-iteration CLI smoke path into a fresh output directory, and reconfirmed that the repository is built to the structure spec. The conclusion remains unchanged: the only remaining blocker for live non-zero docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; pdbqt = prepare_smiles('CC(=O)Oc1ccccc1C(=O)O'); assert pdbqt is not None; assert 'TORSDOF' in pdbqt; print('Phase 1 OK')"` -> `Phase 1 OK`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agent_and_build_current_turn` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agent_and_build_current_turn/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current Turn Build Validation 4

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace again found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a new request-scoped verification artifact from the repaired `.venv` path rather than relying on the previous validation chain. I re-read the governing instructions, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; pdbqt = prepare_smiles('CC(=O)Oc1ccccc1C(=O)O'); assert pdbqt is not None; assert 'TORSDOF' in pdbqt; print('Phase 1 OK')"` -> `Phase 1 OK`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_turn_4` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_turn_4/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current Prompt Live Validation 2

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a new request-scoped verification artifact from the current `.venv` environment instead of relying on the earlier validation chain. I re-read the governing instructions, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reran the zero-iteration CLI smoke path into a fresh output directory, and reconfirmed that the seed corpus still contains the documented 10,000 entries. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; pdbqt = prepare_smiles('CC(=O)Oc1ccccc1C(=O)O'); assert pdbqt is not None; assert 'TORSDOF' in pdbqt; print('Phase 1 OK')"` -> returned a PDBQT containing `TORSDOF`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_current_prompt` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- `wc -l seeds/zinc_druglike_10k.smi` -> `10000 seeds/zinc_druglike_10k.smi`

## Future Work

Install a supported docking binary such as `gnina` or `vina` on this machine so the already-implemented non-zero docking phases can be exercised end-to-end. That would unlock live verification of the docking, parser, coverage, oracle, and main-loop milestones under real runtime conditions; the main challenge is managing the extra system-level dependency and any model/runtime assets required by the chosen docking engine.

## Phase Summary: Current Request Live Snapshot

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a fresh request-scoped verification snapshot from the validated `.venv` environment instead of relying on the earlier `.agent/` confirmation chain. I re-read the governing instructions, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; pdbqt = prepare_smiles('CC(=O)Oc1ccccc1C(=O)O'); assert pdbqt is not None; assert 'TORSDOF' in pdbqt; print('Phase 1 OK')"` -> returned a PDBQT containing `TORSDOF`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_current_request_live` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_current_request_live/{coverage.json,corpus/state.json,corpus.json}`

## Phase Summary: Current Request Build Now

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a fresh current-request verification artifact from the validated `.venv` path instead of relying on the earlier `.agent/` history. I re-read the governing instructions, re-read the key runtime modules that define the entrypoint, main loop, ligand preparation path, and docking wrapper, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, and reran the zero-iteration CLI smoke path into a fresh output directory. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; pdbqt = prepare_smiles('CC(=O)Oc1ccccc1C(=O)O'); assert pdbqt is not None; assert 'TORSDOF' in pdbqt; print('Phase 1 OK')"` -> `Phase 1 OK`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_current_request_build_now` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_current_request_build_now/{coverage.json,corpus/state.json,corpus.json}`

## Future Work

Install a supported docking binary such as `gnina` or `vina` on this machine so the already-implemented non-zero docking phases can be exercised end-to-end. That would unlock live verification of the docking, parser, coverage, oracle, selectivity, and main-loop milestones under real runtime conditions; the main challenge is managing the additional system-level dependency and any required runtime assets for the chosen engine.

## Phase Summary: Current Prompt Runtime Validation 3

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing another request-scoped verification artifact from the current `.venv` environment rather than relying on the earlier `.agent/` validation chain. I re-read the governing instructions, reconfirmed the expected repository structure, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reconfirmed the seed corpus still contains the documented 10,000 entries, and reran the zero-iteration CLI smoke path into a fresh output directory. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python - <<'PY' ... PY` -> `Phase 1 OK`
- `wc -l seeds/zinc_druglike_10k.smi` -> `10000 seeds/zinc_druglike_10k.smi`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_prompt_runtime_validation_3` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_prompt_runtime_validation_3/{coverage.json,corpus/state.json,corpus.json}`

## Future Work

Install a supported docking binary such as `gnina` or `vina` on this machine so the already-implemented non-zero docking phases can be exercised end-to-end. That would unlock live verification of the docking, parser, coverage, oracle, selectivity, and main-loop milestones under real runtime conditions; the main challenge is managing the additional system-level dependency and any required runtime assets for the chosen engine.

## Phase Summary: Current Prompt Runtime Validation 2

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a fresh prompt-scoped verification snapshot from the current `.venv` environment instead of relying on the earlier `.agent/` validation chain. I re-read the governing instructions, reconfirmed the expected repository structure under `biofuzz/`, `targets/`, `scripts/`, and `tests/`, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reconfirmed the seed corpus still contains the documented 10,000 entries, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python - <<'PY' ... PY` -> `Phase 1 OK`
- `wc -l seeds/zinc_druglike_10k.smi` -> `10000 seeds/zinc_druglike_10k.smi`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_prompt_runtime_validation_2` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_review_agents_and_build_current_prompt_runtime_validation_2/{coverage.json,corpus/state.json,corpus.json}`

## Future Work

Install a supported docking binary such as `gnina` or `vina` on this machine so the already-implemented non-zero docking phases can be exercised end-to-end. That would unlock live verification of the docking, parser, coverage, oracle, selectivity, and main-loop milestones under real runtime conditions; the main challenge is managing the additional system-level dependency and any required runtime assets for the chosen engine.

## Phase Summary: Current Workspace Fresh Validation 2

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a fresh request-scoped verification artifact from the current `.venv` environment instead of relying on the earlier `.agent/` validation chain. I re-read the governing instructions, re-read the key runtime modules for the entrypoint, main loop, config layering, docking wrapper, preparation path, and runtime audit, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reconfirmed the seed corpus still contains the documented 10,000 entries, and reran the zero-iteration CLI smoke path into a fresh output directory. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -v` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python -c "from biofuzz.molecules.preparation import prepare_smiles; pdbqt = prepare_smiles('CC(=O)Oc1ccccc1C(=O)O'); assert pdbqt is not None; assert 'TORSDOF' in pdbqt; print('Phase 1 OK')"` -> returned a PDBQT containing `TORSDOF`
- `wc -l seeds/zinc_druglike_10k.smi` -> `10000 seeds/zinc_druglike_10k.smi`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_491fbd2eb1c640c8929d5a0851e1514c` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_491fbd2eb1c640c8929d5a0851e1514c/{coverage.json,corpus/state.json,corpus.json}`

## Future Work

Install a supported docking binary such as `gnina` or `vina` on this machine so the already-implemented non-zero docking phases can be exercised end-to-end. That would unlock live verification of the docking, parser, coverage, oracle, selectivity, and main-loop milestones under real runtime conditions; the main challenge is managing the additional system-level dependency and any required runtime assets for the chosen engine.

## Phase Summary: Current Prompt Venv Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live workspace found that the repository already satisfies the documented package layout, phase/module split, targets, scripts, configuration, entrypoint, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was producing a fresh prompt-scoped verification snapshot from the validated `.venv` environment instead of relying on the earlier `.agent/` confirmation chain or the weaker system `python3` environment. I re-read the governing instructions, re-read the key runtime modules for the entrypoint, main loop, config layering, docking wrapper, preparation path, and runtime audit, confirmed the repository remains on `develop`, reran the full test suite, reran the runtime dependency audit, reran the Phase 1 preparation criterion, reconfirmed the seed corpus still contains the documented 10,000 entries, reran the zero-iteration CLI smoke path into a fresh output directory, and confirmed that the documented run layout was produced with `coverage.json`, `corpus/state.json`, and the mirrored `corpus.json`. The conclusion remains unchanged: BioFuzz is built to the structure spec in the repository, while the only remaining blocker for live non-zero chemistry and docking runs is the absence of a supported docking binary on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `51 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: False`; `PyYAML`, `RDKit`, and `Meeko` available; `gnina`, `vina`, `quickvina2`, and `quickvina-w` unavailable in the current workspace
- `./.venv/bin/python - <<'PY' ... PY` -> `phase1_ok: True`; `torsdof_present: True`
- `wc -l seeds/zinc_druglike_10k.smi` -> `10000 seeds/zinc_druglike_10k.smi`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 0 --workers 1 --output runs/smoke_cli_2026_03_30_request_build_current_prompt_venv` -> successful completion with `iterations=0`, `hits=0`, `coverage_ratio=0.0`, `corpus_size=10000`, and `best_affinity=0.0`
- Output audit -> confirmed `runs/smoke_cli_2026_03_30_request_build_current_prompt_venv/{coverage.json,corpus/state.json,corpus.json}`

## Future Work

Install a supported docking binary such as `gnina` or `vina` on this machine so the already-implemented non-zero docking phases can be exercised end-to-end. That would unlock live verification of the docking, parser, coverage, oracle, selectivity, and main-loop milestones under real runtime conditions; the main challenge is managing the additional system-level dependency and any required runtime assets for the chosen engine.

## Phase Summary: Local Vina And Real Target Validation

This phase closed the remaining gap between a structurally complete BioFuzz repository and a genuinely runnable local build. The earlier implementation already matched `BIOFUZZ_STRUCTURE.md` in package layout and phase wiring, but two practical blockers remained: there was no supported docking binary on the machine, and the checked-in HIV protease target fixtures were still placeholders that could not satisfy the reference-docking milestone realistically.

The successful approach was to solve both problems inside the repository. I added a small `.agent/tools/install_vina.py` installer that downloads the official AutoDock Vina binary into `.agent/tools/bin/vina`, then updated the docking runner and runtime audit so BioFuzz discovers repo-local binaries as part of normal runtime resolution. I also replaced the placeholder `indinavir.pdbqt` with a Meeko-prepared ligand generated from the checked-in reference SMILES, prepared a real HIV protease receptor from the `1HSG` crystal structure using `.venv/bin/mk_prepare_receptor.py`, and updated the target docking-box center to the co-crystal ligand centroid. That made the documented reference-docking flow succeed end-to-end against the checked-in target assets rather than only against ad hoc temporary files.

The main challenge was that the failure mode was split across environment and fixture quality. Installing Vina alone was not enough because the placeholder receptor and ligand still produced invalid or uninformative docking results, while replacing the target fixtures alone would still leave the workspace unable to execute docking runs. The fix therefore had to combine runtime tooling, target data repair, and a small regression-test update so the new local-binary fallback remained deterministic in the suite.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `52 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: True`; `vina` resolved from `.agent/tools/bin/vina`
- Phase 1 criterion -> aspirin preparation produced PDBQT containing `TORSDOF`
- Reference docking/parser/coverage flow -> `phase2_success: True`, `phase3_best_affinity: -9.936`, `phase3_pose_atoms: 48`, `phase4_new_bits: 10`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 1 --workers 1 --output runs/smoke_cli_2026_03_30_real_vina_validation` -> successful completion with `iterations=1`, `hits=0`, `coverage_ratio=0.20833333333333334`, `corpus_size=10000`, and `best_affinity=-8.625`

## Future Work

The current HIV protease target now supports real local docking, but the remaining improvement would be upgrading the simplified pocket-residue model so coverage fingerprints distinguish residue identity by chain as well as residue number. That would avoid collisions between homologous residues across the protease dimer and make the coverage signal closer to the true binding interface. The main challenge is that this change would touch the residue parser, pocket fingerprint representation, stored coverage checkpoints, and any tests or persistence that currently assume residue IDs are single integers.

## Phase Summary: Live Workspace Snapshot

This request asked for another review of `.agent/AGENTS.md` and for BioFuzz to be built as defined by `BIOFUZZ_STRUCTURE.md`. The repository did not require new functional source changes during this pass because the current workspace already contains the documented package layout, target assets, scripts, config layering, runtime modules, and tests, and it is now capable of executing the spec's early-to-middle phases against real checked-in assets.

The useful work in this phase was a fresh live verification sweep tied directly to the structure document rather than another smoke-only confirmation. I reran the test suite from `.venv`, reran the runtime audit, executed the Phase 1 preparation criterion on aspirin, ran the checked-in indinavir reference ligand through docking and parsing, confirmed the resulting pose expands the coverage bitmap against the HIV protease pocket definition, confirmed the oracle marks that reference dock as a hit, and then ran a fresh one-iteration CLI fuzzing pass. That verification showed the current workspace can exercise phases 1 through 8 on a real local runtime path, with the remaining later-phase improvements being tuning work rather than missing build functionality.

Validation performed:

- `./.venv/bin/python -m pytest tests -q` -> `52 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py --json` -> `live_run_ready: true`; `vina` resolved from `.agent/tools/bin/vina`
- Phase 1 criterion -> aspirin preparation returned PDBQT containing `TORSDOF`
- Reference docking flow -> `phase2_success: True`, `phase3_best_affinity: -9.977`, `phase3_pose_atoms: 48`, `phase4_new_bits: 11`, `phase5_is_hit: True`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 1 --workers 1 --output runs/request_2026_03_29_build_validation` -> successful completion with `iterations=1`, `hits=0`, `coverage_ratio=0.375`, `corpus_size=10000`, and `best_affinity=-8.739`

## Future Work

The next meaningful improvement is to add a high-signal end-to-end regression that exercises a tiny real docking loop from the CLI while keeping runtime low, so future refactors cannot silently break the current live-run path. The main challenge is making that test deterministic and fast enough for routine execution while still using realistic docking outputs.

## Phase Summary: Current Request Live Run Confirmation

This request asked for another review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the live repository found that the current implementation still already satisfies the documented package layout, phase split, targets, scripts, runtime modules, and test coverage, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was proving the current workspace state directly from the checked-in `.venv` toolchain rather than depending on the earlier request log chain. I re-read the key runtime modules, confirmed the workspace remains on `develop`, reran the runtime audit, reran the full test suite, reconfirmed the 10,000-entry seed corpus and HIV protease assets, executed a direct Phase 1-5 validation script against the checked-in target, and ran a fresh one-iteration CLI fuzzing pass. That showed the repository is not only structurally aligned with the spec but also runnable through the documented preparation, docking, parsing, coverage, oracle, and main-loop flow on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: True`; repo-local `vina` resolved from `.agent/tools/bin/vina`
- `./.venv/bin/python -m pytest tests -q` -> `52 passed`
- `wc -l seeds/zinc_druglike_10k.smi` -> `10000 seeds/zinc_druglike_10k.smi`
- Direct Phase 1-5 validation -> `phase1_prepare_ok: True`, `best_affinity: -10.05`, `pose_atoms: 48`, `fingerprint_bits: 11`, `oracle_hit: True`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 1 --workers 1 --output runs/smoke_cli_2026_03_29_current_build_request` -> successful completion with `iterations=1`, `hits=0`, `coverage_ratio=0.375`, `corpus_size=10000`, and `best_affinity=-8.77`

## Future Work

The next useful improvement is a compact, deterministic end-to-end regression that exercises the current real docking path from the CLI against the checked-in HIV protease assets. That would protect the now-working live run path from silent breakage during future refactors; the main challenge is keeping runtime low and results stable enough for routine test execution.

## Phase Summary: Current Request Live Phase Revalidation

This request asked for another review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh audit of the live repository found that the current implementation still already satisfies the documented package layout, phase split, targets, scripts, runtime modules, and test coverage, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was extending verification beyond the earlier preparation-through-oracle checks. I reran the full test suite from the checked-in `.venv`, reran the runtime audit to confirm repo-local `vina` availability, rechecked the 10,000-entry seed corpus, executed a direct Phase 1-5 script against the HIV protease target, executed direct Phase 6-7 checks for corpus ordering and mutation validity, and then ran fresh live CLI executions for both the one-worker and two-worker paths. That showed the repository is not only structurally aligned with the spec but also runnable through the documented preparation, docking, parsing, coverage, oracle, corpus, mutation, main-loop, and multiprocessing flow on this machine.

Validation performed:

- `./.venv/bin/python -m pytest tests -q` -> `52 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py --json` -> `live_run_ready: true`; `vina` resolved from `.agent/tools/bin/vina`
- `wc -l seeds/zinc_druglike_10k.smi` -> `10000 seeds/zinc_druglike_10k.smi`
- Direct Phase 1-5 validation -> `phase1_ok=True`, `phase2_ok=True`, `phase3_best_affinity=-9.949`, `phase3_atoms=48`, `phase4_new_bits=11`, `phase5_hit=True`
- Direct Phase 6-7 validation -> `phase6_top=c1ccccc1`, `phase7_count=16`, all mutants parse successfully, and the input phenol SMILES was not returned
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 1 --workers 1 --output runs/request_2026_03_29_live_check` -> successful completion with `iterations=1`, `hits=0`, `coverage_ratio=0.3333333333333333`, `corpus_size=10000`, and `best_affinity=-8.638`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 4 --workers 2 --output runs/request_2026_03_29_parallel_check` -> successful completion with `iterations=4`, `hits=0`, `coverage_ratio=0.4583333333333333`, `corpus_size=10003`, and `best_affinity=-8.938`

## Future Work

The next useful improvement is still a compact, deterministic end-to-end regression that exercises the real CLI docking loop with the checked-in HIV protease assets. The current live path is working, but protecting the one-worker and multiprocessing modes from silent regressions would require a carefully bounded fixture strategy so the test stays stable and fast enough for routine execution.

## Phase Summary: Current Workspace Live Phase Validation

This request again asked for a review of `.agent/AGENTS.md` and for BioFuzz to be built according to `BIOFUZZ_STRUCTURE.md`. A fresh direct audit of the live repository found that the implementation still already satisfies the documented package layout, phase split, targets, scripts, runtime modules, and tests, so no new BioFuzz source-code changes were required for this pass.

The useful work in this phase was re-proving the current workspace directly from the checked-in `.venv` toolchain rather than relying on the long `.agent/` validation history. I re-read the governing instructions, reconfirmed the workspace is on `develop`, reran the test suite, reran the runtime audit, executed a direct Phase 1-7 validation script against the HIV protease target, and reran fresh live CLI executions for both the one-worker and two-worker paths. That showed the current repository is not only structurally aligned with the spec but also runnable through the documented preparation, docking, parsing, coverage, oracle, corpus, mutation, main-loop, and multiprocessing flow on this machine.

Validation performed:

- `git branch --show-current` -> `develop`
- `./.venv/bin/python -m pytest tests -q` -> `52 passed`
- `./.venv/bin/python .agent/tools/runtime_audit.py` -> `live_run_ready: True`; `vina` resolved from `.agent/tools/bin/vina`
- Direct Phase 1-7 validation -> `phase1_ok=True`, `phase2_ok=True`, `phase3_best_affinity=-9.986`, `phase3_atoms=48`, `phase4_new_bits=11`, `phase5_hit=True`, `phase6_top=c1ccccc1`, `phase7_count=16`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 1 --workers 1 --output runs/request_2026_03_30_current_turn_live_1w` -> successful completion with `iterations=1`, `hits=0`, `coverage_ratio=0.375`, `corpus_size=10000`, and `best_affinity=-8.746`
- `./.venv/bin/python main.py --target hiv_protease --max-iterations 4 --workers 2 --output runs/request_2026_03_30_current_turn_live_2w` -> successful completion with `iterations=4`, `hits=0`, `coverage_ratio=0.4166666666666667`, `corpus_size=10003`, and `best_affinity=-8.76`

## Future Work

The next useful improvement is still a compact, deterministic end-to-end regression that exercises the real CLI docking loop with the checked-in HIV protease assets in both one-worker and multiprocessing modes. The current live path is working, but protecting both execution modes from silent regressions would require a carefully bounded fixture strategy so the test stays stable and fast enough for routine execution.
